Eight Rheumatic Diseases with One Blood Draw

ANA IFA Cascade with IdentRA^® (test code 94954) panel combines sensitivity and specificity of various markers to aid in differential diagnosis for the eight most common rheumatic diseases:

• Systemic Lupus Erythematosus (SLE)
• Mixed Connective Tissue Disease
• Systemic Sclerosis
• Rheumatoid Arthritis (RA)
• Sjögren’s Syndrome
• Polymyositis
• CREST Syndrome
• Neuropsychiatric SLE
   

ANA IFA Cascade with IdentRA^®:

• Screens antinuclear autoantibodies (ANA) using the gold standard, highly sensitive immunofluorescence assay (IFA) with HEp-2 cells
• Automatically reflexes a positive ANA screen to a tiered cascade of specific antibodies for a complete result
• IdentRA^® panel components include:
  • Widely used RA markers RF (rheumatoid factor) and CCP (cyclic citrullinated peptide)
  • Serum 14-3-3η (eta) protein, a marker for RA that improves identification of early and established RA^1,2,3 in addition to providing prognostic information^4,5
     

When in-office testing is not an option, your local Quest Diagnostics Patient Service Centers can provide the testing that you and your at-risk patients need. Quest Diagnostics offers the Peace of Mind program to enable your vulnerable or immunocompromised patients to get the non-COVID-19 lab testing they need in a clean environment that is designed to minimize a patient's interactions.

1. Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol. 2002;29:2074-2076.
   
2. Maksymowych WP, Naides SJ, Bykerk V, et al. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol. 2014;41:2104-2113.
3. Naides SJ, Marotta A. 14-3-3η in “seronegative” rheumatoid arthritis. J Rheumatol. 2015;42(10):1995.
4. Carrier N, Marotta A, de Brum-Fernandes AJ, et al. Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis. Arthritis Res Ther. 2016;18:37.
5. van Beers-Tas MH, Marotta A, Boers M, et al. A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia. Arthritis Res Ther. 2016;18:76.